Sign in Register

Drug class

GI Stimulants

Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives. Read more about GI Stimulants

40 drugs in this class 38 manufacturers

Related classes & indications

Proton Pump InhibitorsGastrointestinal · 219 prescription drugs Histamine-2 Receptor Antagonists (H2 Antagonists)Gastrointestinal · 78 prescription drugs Diabetic GastroparesisTop indication · 44 prescription drugs

Showing 1–9 of 40 drugs

Sort

METOCLOPRAMIDE HCL

ANTIEMETIC · GASTROESOPHAGEAL REFLUX DISEASE ·+1

ANI PHARMACEUTI

REGLAN (metoclopramide HCl)

ANTIEMETIC · GASTROESOPHAGEAL REFLUX DISEASE ·+1

ANI PHARMACEUTI

METOCLOPRAMIDE HCL

ANTIEMETIC · GASTROESOPHAGEAL REFLUX DISEASE ·+1

AHP

METOCLOPRAMIDE HCL

ANTIEMETIC · GASTROESOPHAGEAL REFLUX DISEASE ·+1

TEVA USA

METOCLOPRAMIDE HCL

ANTIEMETIC · GASTROESOPHAGEAL REFLUX DISEASE ·+1

MYLAN INSTITUTI

METOCLOPRAMIDE HCL

ANTIEMETIC · GASTROESOPHAGEAL REFLUX DISEASE ·+1

PHARMACEU ASSOC

METOCLOPRAMIDE HCL

ANTIEMETIC · GASTROINTESTINAL RADIOGRAPHY ADJUNCT ·+4

Teva Parenteral Medicines

METOCLOPRAMIDE HCL

ANTIEMETIC · GASTROINTESTINAL RADIOGRAPHY ADJUNCT ·+4

NOVAPLUS/TEVA

METOCLOPRAMIDE HCL

ANTIEMETIC · GASTROINTESTINAL RADIOGRAPHY ADJUNCT ·+4

Hospira

Filter & compare in the drug finder → Opens the drug finder with GI Stimulants preselected. Add indication or manufacturer filters there.

About GI Stimulants.

Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives.

These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT4 receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying.

Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia syndromes.

nih.gov
Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives
nih.gov
Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives
drugs.com
Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia...
nih.gov
These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying
pharmacytimes.com
These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying
truemeds.in
These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refrac...
aacnjournals.org
These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying
drugs.com
Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia syndromes
nih.gov
Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia syndromes